公开(公告)号：US20210403557A1

公开(公告)日：2021-12-30

申请号：US17288641

申请日：2019-11-04

申请人： Mingmei CAI ,  Elliot K. CHARTASH ,  Jane Anne HEALY ,  Mallika LALA ,  Tommy Ruosi LI ,  Kapil MAYAWALA ,  Raluca Andreia PREDOIU ,  Sybil M.G. WILLIAMS ,  Zhen ZENG ,  Merck Sharp & Dohme Corp.

发明人： Mingmei Cai ,  Elliot K. Chartash ,  Jane Anne Healy ,  Mallika Lala ,  Tommy Ruosi Li ,  Kapil Mayawala ,  Raluca Andreia Predoiu ,  Sybil M.G. Williams ,  Zhen Zeng

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody.